TransThera Sciences’ Tinengotinib Gains FDA Fast Track for mCRPC Treatment
China-headquartered TransThera Sciences (Nanjing) Inc., (HKG: 2617), which listed in Hong Kong this week, announced...
XtalPi Signs LOI With DoveTree for AI-Powered Drug Development
Shenzhen-based QuantumPharm Inc., known as Xtalpi Inc. (HKG: 2228), announced the signing of a Letter...
Merck’s Prevymis Approved in China for Pediatric CMV Prevention
US-based pharmaceutical giant Merck, Sharp & Dohme (MSD, NYSE: MRK) announced that its novel non-nucleoside...
Sansure Biotech Wins NMPA Approval for Fungal Infection Detection Kit
China’s National Medical Products Administration (NMPA) has approved Sansure Biotech Inc.’s (SHA: 688289) Pneumocystis jirovecii,...
Broncus Medical Wins NMPA Approval for BroncAblate RFA System Console
Shanghai and Hangzhou (China), and San Jose and Seattle (United States)-based Broncus Medical (HKG: 2216)...
NHSA Implements Region-Based Pricing System for Medical Services
China’s National Healthcare Security Administration (NHSA) this week issued the “Notice on Optimizing Medical Service...
Insilico Medicine Partners with UAEU to Drive Biotech Innovation in the Middle East
China-based generative artificial intelligence (AI)-driven biotech Insilico Medicine this week entered into a strategic Memorandum...
Bio-Thera Partners with SteinCares for Biosimilar Commercialization in Latin America
Guangzhou-based Bio-Thera Solutions Ltd. (SHA: 688177) and Costa Rica-based SteinCares have entered into a licensing...
Vcanbio Submits Clinical Trial Application for VUM02 in Severe Pneumonia Treatment
China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) announced that its clinical trial...
Simcere Halts R&D on Alzheimer’s Drug Candidates Amid Pipeline Setbacks
Simcere Pharmaceutical Group (HKG: 2096) has reportedly discontinued research and development of its Alzheimer’s disease...
Yifan Pharma Wins NMPA Approval for Norditropin Biosimilar Trial
China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) announced that it has received clinical trial approval...
GSK’s Linerixibat Accepted for EMA Review for Cholestatic Pruritus in PBC
UK-based GlaxoSmithKline (GSK; NYSE: GSK) announced that the European Medicines Agency (EMA) has accepted the...
Sanofi’s Sarclisa Recommended for EU Approval in Newly Diagnosed Multiple Myeloma
France major Sanofi (NASDAQ: SNY) announced that the European Medicines Agency’s (EMA) Committee for Medicinal...
Beijing Tightens Price Risk Management for Scarce Medications
The Beijing Municipal Medical Insurance Bureau issued the “Notice on Further Strengthening Price Risk Management...
Cloudbreak Pharma’s IPO Raises HKD 522M for Ophthalmic Drug Development
Clinical-stage ophthalmic biotech Cloudbreak Pharma Inc. has successfully completed an initial public offering (IPO) of...
Formation Bio Licenses Gusacitinib to Sanofi for Novel Indication Study
US-based AI-native pharma company Formation Bio announced the licensing of gusacitinib, an oral dual JAK/SYK...
Novo Nordisk’s Ozempic Gets Positive CHMP Opinion for Peripheral Artery Disease
Denmark-based Novo Nordisk A/S (NYSE: NVO) announced that the European Medicines Agency’s (EMA) Committee for...
Illumina to Acquire SomaLogic for $350M to Expand Proteomics Tech Integration
US major Illumina (NASDAQ: ILMN) announced plans to acquire SomaLogic, a leader in data-driven proteomics...
Denovo Biopharma Inks Licensing Deal With Chuang Yi for DB104 in Taiwan
Denovo Biopharma, a US-headquartered precision medicine company with significant operations in China, announced a licensing...
Hengrui Pharmaceuticals Wins NMPA Approval for Six Novel Solid Tumor Drugs
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced receiving clinical trial approvals from the...